Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.
The Conference on Retroviruses and Opportunistic Infections 2026 included breakthrough research and looked toward the future of HIV.
The data in these posters address a central clinical question: can a topical JAK1/JAK2 inhibitor deliver robust efficacy while maintaining a reassuring safety profile?
Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs.
Food-insecure adults have fewer annual health visits but rely more on telehealth for primary care, lowering per-visit costs, says Bidisha Mandal, PhD.
National data reveal increasing rates of type 1 and type 2 diabetes among children insured through Medicaid and CHIP.
Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.
Socioeconomic adversity in the perinatal period drives widening low birth weight gaps, fueling adverse pregnancy outcomes and deepening maternal and infant health inequities.
The Center for Innovation & Value Research announces the launch of resources to guide collaboration with patients and caregivers in comparative effectiveness research.
Environmental factors were a barrier to participation in community activities among people with multiple sclerosis, even after adjusting for personal factors like disease severity.
A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.
Clinical measures and biomarkers during pregnancy, including hs-cTnI and sFlt-1, can help identify women at higher risk of developing cardiovascular disease later in life.
In a cohort of veterans with steatotic liver disease, patients with metabolic- and alcohol-associated liver disease had the lowest incidence of cirrhosis.
Employers and members can cut GLP-1 weight-loss costs with carve-outs, split payments, and transparent, updated price guides.
Patients with both a low estimated glomerular filtration rate and a high protein-to-creatinine ratio were at particularly high risk of cognitive impairment, a new study has found.
Transcriptomic analysis revealed that chronic hand eczema shares overlapping immune signatures with both atopic dermatitis and psoriasis.
Meta-analysis links obstructive sleep apnea to early kidney injury markers, especially in severe OSA and hypertension, highlighting need for renal monitoring.
Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, sex, race, and US region.
Treatment for multiple myeloma often confers a higher risk of subsequent cardiovascular disease, but the impact of medications for the latter in this setting is not fully understood.
Survey flags GLP-1 cost hurdles as nurses win staffing protections, new trauma center cuts shooting deaths, and understaffing data sharpen care debates.
Recent guideline updates for squamous cell skin cancer add adjuvant cemiplimab as a preferred option for certain patients with very high-risk disease.
More than 57% of patients with ACD reported moderate to severe quality-of-life impairment, with symptoms and embarrassment among the most affected areas.
Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks transparency, which may lower uptake.
A Mississippi hospital partners with Eko Health to introduce AI-assisted cardiac detection in underserved rural communities.
Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.
Scripta allows consumers to compare prescription prices, coupons, and insurance options in one place, helping patients and employers find affordable meds and smarter choices.
High area level housing cost burden is associated with increased cardiovascular hospitalizations and emergency department use among Medicaid beneficiaries.
Enfortumab vedotin plus pembrolizumab boosts survival and pCR in muscle-invasive bladder cancer, according to EV-304 trial data.
Measles outbreaks are emerging across the country, continuing the increasing trend in cases that began in 2025.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
